バロフロキサシン
バロフロキサシン 物理性質
- 融点 :
- 137°C
- 沸点 :
- 608.3±55.0 °C(Predicted)
- 比重(密度) :
- 1.40±0.1 g/cm3(Predicted)
- 貯蔵温度 :
- Keep in dark place,Inert atmosphere,2-8°C
- 溶解性:
- H2O : < 0.1 mg/mL (insoluble)DMSO : 0.67 mg/mL (1.72 mM; Need ultrasonic)
- 酸解離定数(Pka):
- 6.44±0.50(Predicted)
- BRN :
- 8362117
- CAS データベース:
- 127294-70-6(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
警告 |
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H228 |
可燃性固体 |
可燃性固体 |
1
2 |
危険
警告 |
|
P210, P240,P241, P280, P370+P378 |
|
| 注意書き |
|
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-7920 |
バロフロキサシン
Balofloxacin |
127294-70-6 |
1g |
￥20000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-7920 |
バロフロキサシン
Balofloxacin |
127294-70-6 |
5g |
￥60000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-7920 |
Balofloxacin |
127294-70-6 |
10g |
￥105000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-7920 |
Balofloxacin |
127294-70-6 |
25g |
￥210000 |
2024-03-01 |
購入 |
|
富士フイルム和光純薬株式会社(wako)
|
W01COBQA-7920 |
Balofloxacin |
127294-70-6 |
100g |
￥490000 |
2024-03-01 |
購入 |
バロフロキサシン 化学特性,用途語,生産方法
効能
抗菌薬, 核酸合成阻害薬
説明
Balofloxacin, a novel orally-active fluoroquinolone antibiotic, was introduced in South
Korea for the treatment of urinary tract infections (UTI). It can be synthetized by reaction of
3-(methylamino)piperidine with the classical 4-quinolone-3-carboxylic acid template. In
vitro antibacterial activity of balofloxacin against gram-positive bacteria (Staphylococcus
aureus including methicillin-resistant S. aureus, Staphylococcus epidermis, Streptococcus
pneumonia, Streptococcus pyrogenes) was almost equal to that of sparfloxacin or
tosufloxacin, in contrast its activity against gram-negative bacteria was 2 times or more
lower. In clinical trials, balofloxacin was well tolerated and showed comparable efficacy to
ofloxacin in patients with UTls. After oral administration, balofloxacin was well absorbed,
and was primarily eliminated unchanged in the urine with an elimination half-life of
approximately 8 h. In animal studies, balofloxacin did not exhibit any phototoxicity.
化学的特性
Crystalline Solid
使用
Balofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.
応用例（製薬）
A 6-fluoro-8-methoxy quinolone derivative. It has good antistaphylococcal activity (MIC 0.4–4 mg/L), but is inactive against methicillin-resistant Staph. aureus (MRSA) and quinolone-resistant Staph. aureus; Str. pneumoniae is inhibited by 0.4 mg/L. It has good activity against Enterobacteriaceae, but is inactive against Ps. aeruginosa (MIC 8–16 mg/L). After a 200 mg oral dose a peak level of 1.7 mg/L is reached in 1 h. The apparent elimination halflife is about 8 h, rising to 13 h in elderly subjects. Plasma protein binding is about 16%. It was withdrawn from the market in Japan because of adverse events, but is available in China.
バロフロキサシン 上流と下流の製品情報
原材料
準備製品
バロフロキサシン 生産企業
Global( 276)Suppliers
127294-70-6(バロフロキサシン)キーワード:
- 127294-70-6
- 3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-Methoxy-7-[3-(MethylaMino)-1-piperidinyl]-4-oxo-
- 1-Cyclopropyl-6-fluoro-8-Methoxy-7-(3-(MethylaMino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
- 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-(methylamino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-c
- 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-(methylamino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-
- Balofloxacin, >=99%
- 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid
- BALOFLOXACIN
- 3-quinolinecarboxylicacid,1,4-dihydro-1-cyclopropyl-6-fluoro-8-methoxy-7-(3-(
- q35
- BALOFLOXACIN 98.5% EXTRA PURE
- BALOFLOXACIN 98.5%
- Balofloxacin 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3 carboxylic acid 1-Cyclopropyl-6-Fluoro-1,4-Dihydro-8-Methoxy-7-[3-(Methylamino)-1-Piperidino]-4-Oxo-3-Quinoline Carboxylic Acid(Balofloxacin)
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidino]-4-oxo-3-quinolinecarboxylicacid
- (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)piperidino]-4-oxo-3-quinolinecarboxylic Acid
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-3-quinolinecarboxylic Acid
- 1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-methylamino-1-piperidyl)-4-oxo-quinoline-3-carboxylic acid
- 1-Cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic
- Balofloxacin hydrate
- Balofloxacin425.46
- Balofloxacin USP/EP/BP
- BalofloxacinQ: What is
Balofloxacin Q: What is the CAS Number of
Balofloxacin Q: What is the storage condition of
Balofloxacin Q: What are the applications of
Balofloxacin
- Barlow of sand
- Balofloxacin/1-Cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid
- 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-3-(methylamino)piperidin-1-yl-4-oxo-quinolin-3-carboxylic acid
- Cypermethrin Impurity 4
- バロフロキサシン
- バロフロキサシン水和物
- バロフロキサシン水和物 (JAN)
- rac-1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-8-メトキシ-7-[3α*-(メチルアミノ)ピペラジノ]-4-オキソ-3-キノリンカルボン酸
- バルフロキサシン
- 1-シクロプロピル-6-フルオロ-8-メトキシ-7-[3-(メチルアミノ)ピペリジン-1-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸
- 1-シクロプロピル-6-フルオロ-1,4-ジヒドロ-8-メトキシ-7-[3-(メチルアミノ)ピペリジノ]-4-オキソ-3-キノリンカルボン酸
- 1-シクロプロピル-6-フルオロ-7-[3-(メチルアミノ)ピペリジノ]-8-メトキシ-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸